Spots Global Cancer Trial Database for pharmacokinetics
Every month we try and update this database with for pharmacokinetics cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) | NCT02913612 | Infantile Heman... | 0.25% Timolol M... 0.5% Timolol Ma... | - 84 Days | Duke University | |
| An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate | NCT01844869 | Hematologic Mal... Solid Tumors | omacetaxine mep... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients | NCT03258099 | Solid Tumor Capecitabine Drug-Related Si... Pharmacogenetic... Pharmacokinetic... | detection of ge... | 18 Years - | Peking University First Hospital | |
| Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers | NCT01079286 | Renal Cell Canc... Cancer | Nelfinavir and ... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies. | NCT00676299 | Protein Kinase ... Antineoplastic ... Clinical Trial,... Maximum Tolerat... Pharmacokinetic... Advanced Malign... Solid Malignanc... | JNJ-26483327 | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients | NCT01902251 | Prostate Cancer Pharmacokinetic... | Enzalutamide ta... Enzalutamide ca... | 18 Years - | Astellas Pharma Inc | |
| A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2) | NCT02235740 | Cancer | Afuresertib Carfilzomib | 18 Years - | Novartis | |
| Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors | NCT02395068 | Solid Tumors | Nimotuzumab irinotecan | 18 Years - 70 Years | Biotech Pharmaceutical Co., Ltd. | |
| Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies | NCT00239239 | Non-Myeloid Mal... Anemia Cancer | Darbepoetin alf... | 18 Years - | Amgen | |
| A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT02406742 | Leukemia, Lymph... | CC-122 Ibrutinib Obinutuzumab | 18 Years - 79 Years | Celgene | |
| Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer | NCT01310478 | Colorectal Neop... | recombinant hum... | 17 Years - 70 Years | Fudan University | |
| A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer | NCT01220999 | Colorectal Neop... | CS-1008 | 18 Years - | Ludwig Institute for Cancer Research | |
| A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients. | NCT06298058 | Advanced Solid ... | SIBP-A13 formul... | 18 Years - 75 Years | Shanghai Institute Of Biological Products | |
| A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors. | NCT05203601 | Tumor | SIBP-03 | 18 Years - 75 Years | Shanghai Institute Of Biological Products | |
| Biomarker Development for Response Prediction by DNA Mutational Analysis | NCT01855061 | Neoplasm Metast... | Biopsy Blood samples Pharmacokinetic... Midazolam clear... | 18 Years - | UMC Utrecht | |
| A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT01594229 | Non-Hodgkin's L... | ABT-199 Rituximab Bendamustine | 18 Years - 99 Years | AbbVie | |
| Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data | NCT00341939 | Prostate Cancer Breast Cancer Cutaneous T-Cel... Lung Cancer Melanoma | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Capivasertib China PK Study | NCT04742036 | Advanced Solid ... | Capivasertib Paclitaxel | 18 Years - 130 Years | AstraZeneca | |
| A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors | NCT01738451 | Cancer | GSK2118436 75 m... Placebo | 18 Years - | GlaxoSmithKline | |
| Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function | NCT01443481 | Solid Tumors Hepatic Impairm... | Dovitinib | 18 Years - | Novartis | |
| Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy | NCT03135951 | Breast Cancer Pharmacokinetic... | SPI-2012 | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Capivasertib China PK Study | NCT04742036 | Advanced Solid ... | Capivasertib Paclitaxel | 18 Years - 130 Years | AstraZeneca | |
| Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function | NCT01443481 | Solid Tumors Hepatic Impairm... | Dovitinib | 18 Years - | Novartis | |
| Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer | NCT01745367 | Triple Negative... | Tivozanib Hydro... paclitaxel Placebo | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors | NCT04088604 | Advanced Solid ... | LY01610 ( Irino... LY01610 ( Irino... Irinotecan Hydr... | 18 Years - 70 Years | Luye Pharma Group Ltd. | |
| Kanglaite Injection Phase I Study | NCT00031031 | Solid Tumors Re... Neoplasms | Kanglaite Injec... | 18 Years - | KangLaiTe USA | |
| A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT01572519 | Relapsed or Ref... | Phase 1, Cohort... Phase 1, Cohort... Phase 1, Cohort... Phase 1, Cohort... Phase 2 | 18 Years - | Janssen Research & Development, LLC | |
| A Study of ASP2138 in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, Pancreatic Cancer | NCT05365581 | Gastric Adenoca... Gastroesophagea... Pancreatic Aden... | ASP2138 | 18 Years - | Astellas Pharma Inc | |
| Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors | NCT00426582 | Advanced Solid ... | Patupilone | 18 Years - | Novartis | |
| Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects | NCT01517399 | Solid Tumors | tivantinib omeprazole s-warfarin caffeine vitamin K digoxin midazolam | 18 Years - | Daiichi Sankyo | |
| Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection. | NCT01302951 | Side-effect of ... | Moxifloxacin 40... | 18 Years - 80 Years | University Hospital, Saarland | |
| A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma | NCT02773030 | Multiple Myelom... | CC-220 Dexamethasone Daratumumab Bortezomib Carfilzomib | 18 Years - | Celgene | |
| Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients | NCT03067350 | Invasive Asperg... Haematological ... Voriconazole | 18 Years - | University Hospital, Grenoble | ||
| Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014 | NCT01026402 | Advanced Solid ... | AZD2014 | 18 Years - 150 Years | AstraZeneca | |
| A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers | NCT02322749 | Healthy Volunte... | selumetinib 75m... selumetinib 75m... selumetinib 75m... | 18 Years - 45 Years | AstraZeneca | |
| A Randomized, Open Label, Clinical Trial of the Pharmacokinetics of Azithromycin Following a Single Dose of Azithromycin Sustained Release (2 Gram) or Commercial Azithromycin Tablet (500 mg) to Cancer Patients That Require Lung Surgery | NCT00644176 | Pharmacokinetic... | azithromycin im... placebo azithromycin SR placebo | 18 Years - | Pfizer | |
| 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study) | NCT04726033 | Metastatic Pros... | 64Cu-DOTA-TLX59... | - | Telix Pharmaceuticals (Innovations) Pty Limited | |
| An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations | NCT02192697 | Non-small Cell ... | ASP8273 | 20 Years - | Astellas Pharma Inc | |
| Validation of an Adjusted Dosing Algorithm of Carboplatin | NCT02103244 | Cancer | Carboplatin | 18 Years - | Rijnstate Hospital | |
| First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410) | NCT04882917 | Advanced Solid ... | M4076 | 18 Years - | EMD Serono | |
| Pharmacokinetics and Metabolic Activation of Capecitabine | NCT01579357 | Metastatic Colo... | blood samples | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies | NCT04883957 | Mature B-cell M... | BGB-11417 | 18 Years - | BeiGene | |
| Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer | NCT03459729 | Squamous Cell C... | Antitumor B | 18 Years - | Medical College of Wisconsin | |
| Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell Transplantation: a Pharmacokinetic Study | NCT00156858 | Hematologic Mal... | intravenous bus... | - 70 Years | AHS Cancer Control Alberta | |
| Predictive Value of Drug Elimination Gene Polymorphisms on Clearance and Dose Adjustment of Sunitinib in Cancer Patients | NCT01098903 | Cancer | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | ||
| Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year | NCT00424983 | Multiple Myelom... Breast Cancer | Zoledronic acid | 18 Years - 75 Years | Novartis | |
| Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma | NCT00600054 | Recurrent Diffu... | nimotuzumab (an... | 3 Years - 18 Years | YM BioSciences | |
| Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer | NCT01310478 | Colorectal Neop... | recombinant hum... | 17 Years - 70 Years | Fudan University | |
| A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | NCT03528629 | Gastric Cancer Gastro-esophage... | Zolbetuximab | 20 Years - | Astellas Pharma Inc | |
| 10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies | NCT00997945 | Advanced Solid ... | ZD4054 (Ziboten... | 50 Years - | AstraZeneca | |
| A Phase 1 Study of AB521 in Renal Cell Carcinoma and Other Solid Tumors | NCT05536141 | Clear Cell Rena... Solid Tumors | AB521 | 18 Years - | Arcus Biosciences, Inc. | |
| TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | NCT01851369 | Lymphomas Solid Tumors NSCLC Metastatic Colo... Granulosa Cell ... | TRC102 CT scan Lomotil Prochlorperazin... Metoclopramide 5-HT3 antagonis... Aprepitant Biopsy | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS | NCT01995981 | Sarcoma, Soft T... | Pazopanib | 18 Years - | Radboud University Medical Center | |
| Broccoli Sprout Intervention in Qidong, P.R. China | NCT01437501 | Environmental C... | Broccoli Sprout... placebo beverag... | 21 Years - 65 Years | Johns Hopkins Bloomberg School of Public Health | |
| Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib | NCT05008913 | Advanced Solid ... | [14C]Adavoserti... | 18 Years - 130 Years | AstraZeneca | |
| A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer | NCT00001446 | Prostatic Neopl... | thalidomide | - | National Institutes of Health Clinical Center (CC) | |
| Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma | NCT02715843 | Non-Hodgkin's B... | MT-3724 | 18 Years - | Molecular Templates, Inc. | |
| Topotecan Pharmacokinetic Characterization Study | NCT00361803 | Cancer | topotecan | 18 Years - | GlaxoSmithKline | |
| Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan | NCT01226550 | Peritoneal Carc... | cytoreductive s... | 18 Years - 64 Years | Hospices Civils de Lyon | |
| Study on Umorestat Hydrogen Sulfate Capsule in Patients With Locally Advanced/Metastatic Pancreatic Cancer | NCT05329597 | Pharmacokinetic... Pancreatic Canc... Gene Polymorphi... | Genotyping | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors | NCT06235983 | Advanced Solid ... | LY3537982 | 18 Years - | Eli Lilly and Company | |
| A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma | NCT00315731 | Lymphoma, Folli... | Follicular Lymp... | 18 Years - | GlaxoSmithKline | |
| Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan | NCT01226550 | Peritoneal Carc... | cytoreductive s... | 18 Years - 64 Years | Hospices Civils de Lyon | |
| A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease | NCT01024036 | Multicentric Ca... | Siltuximab Placebo Best Supportive... | 18 Years - | Janssen Research & Development, LLC | |
| A Drug Monitoring Study on PEG-asparaginase Treatment in Children Diagnosed Acute Lymphoblastic Leukaemia | NCT01272440 | Acute Lymphobla... | 1 Year - 18 Years | Aarhus University Hospital | ||
| Oxaliplatin to Treat Advanced Cancers With Liver Dysfunction | NCT00006062 | Liver Disease | oxaliplatin | - | National Institutes of Health Clinical Center (CC) | |
| An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies | NCT05469919 | Advanced Solid ... | Ceralasertib | 18 Years - | AstraZeneca | |
| A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia | NCT03625505 | Acute Myeloid L... | Venetoclax Gilteritinib | 18 Years - | AbbVie | |
| A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer | NCT01763645 | Non-small Cell ... | Bevacizumab Paclitaxel Carboplatin | 18 Years - 75 Years | Biocad | |
| Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors | NCT04686383 | Resistant or Re... | CAL056 mesylate | 18 Years - | Calgent Biotechnology Co., Ltd | |
| Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya | NCT06263582 | Cervix Cancer Cervix Intraepi... Cervix; Intraep... Cervix; Intraep... | Artesunate pess... blood draws for... | 18 Years - 65 Years | UNC Lineberger Comprehensive Cancer Center | |
| A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours | NCT04958226 | Solid Tumour | Capivasertib Midazolam | 18 Years - 130 Years | AstraZeneca | |
| A Study of SC-007 in Subjects With Advanced Cancer | NCT03253185 | Colorectal Canc... Gastric Cancer | SC-007 | 18 Years - | AbbVie | |
| Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies | NCT00037817 | Advanced Esopha... Primary Small C... Non-Small-Cell ... Pleural Mesothe... Cancers of Non-... | Decitabine Depsipeptide Celecoxib | 18 Years - 65 Years | National Institutes of Health Clinical Center (CC) | |
| A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199 | NCT01969669 | Non-Hodgkin's L... | ABT-199 Ketoconazole | 18 Years - 99 Years | AbbVie | |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | NCT02573259 | Part 1 MELANOMA SCCHN OVCA SARCOMA OTHER SOLID TUM... Part 1 and 2 NSCLC UROTHELIAL CARC... | PF-06801591 PF-06801591 | 18 Years - | Pfizer | |
| A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | NCT05014139 | Urinary Bladder... Carcinoma in Si... Carcinoma Trans... Non-muscle Inva... NMIBC | Enfortumab vedo... | 18 Years - | Astellas Pharma Inc | |
| Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy | NCT02324998 | Prostate Cancer | Olaparib Degarelix | 18 Years - 73 Years | Cambridge University Hospitals NHS Foundation Trust | |
| Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer | NCT01324323 | Hematologic Mal... Malignant Lymph... | Romidepsin Rifampin | 18 Years - | Celgene | |
| IPG7236 in Patients With Advanced Solid Tumors | NCT05142592 | Safety Issues Tolerability Pharmacokinetic... | IPG7236 | 18 Years - | Nanjing Immunophage Biotech Co., Ltd |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
